NICE flip-flops to back J&J's Imbruvica in mantle cell lymphoma

Imbruvica
England's cost-effectiveness gatekeepers now recommend Imbruvica for MCL patients who have had just one prior line of treatment.

With just-arrived competition in mantle cell lymphoma, Johnson & Johnson’s Imbruvica has snagged reimbursement backing in an important new market.

Thursday, England’s National Institute for Health and Care Excellence (NICE) recommended the drug for NHS coverage, flip-flopping on a previous decision not to cover it. But there are conditions: Imbruvica is recommended as a treatment option only for MCL patients who have had just one prior line of therapy.

RELATED: NICE invites angry J&J to make a Cancer Drugs Fund case for Imbruvica

Webinar

Use Serialization Data to Maximize Performance and Minimize Risks

Wednesday, March 18 | 11am ET / 8am PT

Serialized products generate a wealth of data as they move through the supply chain. What if you could access and analyze this data to gain operational visibility and powerful business insight? It’s time to put your serialization investment to work for you.

The other condition, as is often the case with NICE, is that J&J offer up a previously agreed-upon—and confidential—discount. The med in England bears a list price of £4,599.00 for 90×140-mg capsules, or £51.10 per capsule, and £6,132.00 for 120×140-mg capsules.

“We are pleased that patients with this hard-to-treat cancer, who in the past had few treatment options beyond chemotherapy, can now finally access ibrutinib on the NHS in England and Wales,” Jennifer Lee, director of health economics, market access and reimbursement for J&J’s Janssen UK, said in a statement, adding, “Though the process has been lengthy, we have remained steadfast in our commitment to ensuring access to this innovative medicine for those with MCL.”

RELATED: ASH: J&J, AbbVie tout long-term Imbruvica data in the face of a new AstraZeneca threat

The about face comes at a key time for J&J, which just inherited formidable new U.S. competition in the MCL space. In late October, AstraZeneca picked up an FDA approval for Calquence, a future blockbuster analysts think can give Imbruvica a run for its money.

Meanwhile, the Imbruvica-NICE saga stretches beyond MCL. Last year, the cost watchdog rejected the drug in chronic lymphocytic leukemia, instead inviting Janssen to make its case for inclusion in the Cancer Drugs Fund. And last October, it shot down Imbruvica in Waldenstrom's macroglobulinaemia, too. It ultimately changed its mind on those decisions, too, agreeing to cover the drug in both indications.

Suggested Articles

Several of the industry's top players had a strong performance in the fourth quarter, growing revenues at high single digits. Others? Not so much.

Viatris, the merger of Mylan and Pfizer's Upjohn, has fleshed out its board and C-suite with a raft of Pfizer and Mylan veterans.

An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.